The weekly litigation news digest is live. Subscribe now
Methods Of Treating Prostate Cancer - EP3490560
The patent EP3490560 was granted to Janssen Pharmaceutica on Jan 22, 2025. The application was originally filed on Jul 28, 2017 under application number EP17754226A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP3490560
- Application Number
- EP17754226A
- Filing Date
- Jul 28, 2017
- Status
- Granted And Under Opposition
- Dec 20, 2024
- Publication Date
- Jan 22, 2025
- External Links
- Slate, Register, Google Patents
Patent Summary
Niraparib, a PARP inhibitor, is used to treat prostate cancer in patients with DNA repair anomalies, such as BRCA-1 or BRCA-2 mutations. The treatment is effective in patients with castration-resistant prostate cancer, including those who have failed androgen receptor-targeted therapies. Niraparib's mechanism of action involves inducing DNA damage and inhibiting PARP-mediated repair, leading to tumor cell death. The treatment is administered orally and can be used in combination with androgen deprivation therapy.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (2) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents